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Background: Overexpression of GOLPH3 (Golgi phosphoprotein 3, 34 kDa) is associated with the progression of
many solid tumor types leading to an unfavorable clinical outcome. We aimed to investigate the clinical
significance of GOLPH3 expression in the development and progression of clinically N0 (cN0) oral tongue cancer.
Methods: Real-time PCR and Western blotting analyses were employed to examine GOLPH3 expression in four oral
tongue cancer cell lines, primary cultured normal tongue epithelial cells (TEC), eight matched pairs of oral tongue
cancer samples and adjacent noncancerous tissue samples from the same patient. Immunohistochemistry (IHC) was
performed to examine GOLPH3 protein expression in paraffin-embedded tissues from 179 cN0 oral tongue cancer
patients. Statistical analyses were applied to evaluate the diagnostic value and the associations of GOLPH3
expression with clinical parameters.
Results: GOLPH3 mRNA and protein was up-regulated in oral tongue cancer cell lines and cancerous tissues
compared with that in primary cultured normal tongue epithelial cells (TEC) and adjacent noncancerous tissue
samples. GOLPH3 protein level was positively correlated with clinical stage (P= 0.001), T classification (P= 0.001),
N classification (P= 0.043) and recurrence (P= 0.009). Patients with higher GOLPH3 expression had shorter overall
survival time, whereas those with lower GOLPH3 expression had longer survival time.
Conclusion: Our results suggest GOLPH3 overexpression is associated with poor prognosis for cN0 oral tongue
cancer patients and may represent a novel and useful prognostic indicator for cN0 oral tongue cancer.
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Oral cancer is the tenth most commonly diagnosed can-
cer in men worldwide, and cancers of the oral cavity
accounted for 263,900 cases worldwide in 2008 [1]. The
tongue is the most cancer-prone intraoral site in most
populations studied, and the most common pathological
type of oral tongue cancer is squamous cell carcinoma
[2]. Although intensive efforts have been made in pri-
mary prevention and improving therapy, morbidity and* Correspondence: songming@sysucc.org.cn
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reproduction in any medium, provided the ormortality rates for oral tongue cancer remain steadily
high and are rising in a number of countries. Due to its
highly invasive nature, oral tongue cancer frequently
leads to severe defects in speech, mastication and deglu-
tition, as well as cancer-related death. During the last
three decades, the long-term survival rate for patients
with oral tongue cancer has not improved substantially,
and the tongue remains among the worst sites for all
cancers [3]. In clinical practice, although head and neck
surgeons mostly depend on the TNM classification sys-
tem for planning treatment strategy, no consensus exists
on the optimal treatment of the neck in cN0 oral tongue
cancer patients [4]. However, the TNM system is not
sufficiently reliable for predicting clinical outcome or
for providing detailed information on the biologicalhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pression profiling has been reported to predict the clin-
ical outcome more accurately than traditional clinical
and pathological standards [6,7]. Therefore, the identifi-
cation of genes associated with aggressiveness in cN0
oral tongue cancers is of great value in identifying high-
risk patients who may benefit from more aggressive pri-
mary surgery or adjuvant treatment following surgery.
Furthermore, this approach may also provide new tar-
gets for clinical intervention.
It is currently accepted that vesicular trafficking plays
an important role in cancer development. Recently, this
area of cancer research has focused on endocytic path-
ways regulating signal transduction cascades down-
stream of cell surface growth factor receptors [8]. These
pathways play important roles in maintaining a balance
of growth factor signaling and deregulated receptor traf-
ficking, which could provide a mechanism to promote
oncogenesis. The endocytic protein, GOLPH3, is a
highly conserved 34 kDa protein initially identified
through proteomic characterization of the Golgi appar-
atus. GOLPH3 binds to PtdIns(4)P-rich trans-Golgi
membranes and MYO18A, conveying a tensile force
required for efficient tubule and vesicle formation [9-
11]. GOLPH3 gene expression was found to correlate
with 5p13 copy number status in human lung cancer
specimens, and functional studies (RNAi knockdown
and cDNA overexpression) have shown that GOLPH3 is
activated in cancers with 5p amplification and that it is a
bona fide oncogene with potent transforming activity
[12]. Importantly, the correlation between 5p13 copy
number and increased phosphorylation of the p70 S6
kinase mTOR substrate in NSCLC tumor specimens
links GOLPH3 function to mTOR activation [11] and
indicates that GOLPH3 tumorigenesis may be mediated
by mTOR signaling [13]. Although the mechanistic basis
for GOLPH3 activation of mTOR signaling remains un-
clear, several lines of evidence suggest that GOLPH3
plays a role in vesicular trafficking and glycosylation,
which are associated with oncogenicity. Thus, the regu-
lation of mTOR by GOLPH3 may contribute to malig-
nancy through these cellular pathways. GOLPH3
expression levels or copy number status may therefore
serve as a useful prognostic factor for cancer.
In this study, we investigated GOLPH3 expression in a
cohort of cN0 oral tongue cancers to determine the clin-
ical significance of GOLPH3 overexpression in the de-
velopment and progression of cN0 oral tongue cancer.
Methods
Patients and tissue specimens
The specimens were used with prior patients’ written
consent and the approval of the Institutional Research
Ethics Committee of the Sun Yat-sen University CancerCenter. A total of 187 tissue specimens were taken from
patients with cN0 oral tongue cancer, none of whom
had received radiotherapy or chemotherapy prior to sur-
gery. For RT-PCR and Western blotting analysis, eight
matched pairs of tumors tissue and adjacent noncancer-
ous tissue samples were obtained from glossectomy spe-
cimens of patients diagnosed with cN0 oral tongue
cancer immediately after surgery and stored at −80°C.
The percentage tumor purity of these tissues was estab-
lished by the histopathological analysis of adjacent sec-
tions prior to RNA and protein analysis. A total of 179
individual paraffin-embedded cN0 oral tongue cancer
samples were obtained from 107 male and 72 female
patients with a median age of 53 years (range 20 –
87 years), who had been diagnosed using clinical and
histopathological methods at Departments of Head and
Neck Surgery and Departments of Pathology, Sun Yat-
sen University Cancer Center between 1998 and 2005.
Clinical follow-up data was available for a minimum of 5
years or until death. Clinicopathological and immuno-
histochemical analyses of these samples were performed
to determine the prognostic significance of GOLPH3 ex-
pression. All patients received standard therapy based
on the clinical stage. In brief, patients with early-stage
tumors (stages I and II) received surgery alone, whereas
those with advanced-stage cancer (stages III and IV)
received combination therapy comprising surgery and
radiotherapy. Patient progress was followed for
78.3 ± 42.1 months (mean ± SD). The clinical information
this patient cohort is summarized in Table 1.
Cell lines
Four human oral tongue cancer cell lines were pur-
chased from the American Type Culture Collection
(SCC-25 and CAL-27) and the Cell Bank of Type Cul-
ture Collection of Chinese Academy of Sciences (TSCCa
and Tca-8113). SCC-25 and CAL-27 cells were grown in
DMEM (Invitrogen) supplemented with 10% fetal bovine
serum (HyClone Laboratories, Logan, UT). TSCCa and
Tca8113 cells were cultured in RPMI-1640 medium
(GIBCO BRL, Rockville, MD) supplemented with 10%
fetal bovine serum (HyClone Laboratories, Logan, UT).
Primary cultured normal tongue epithelial cells (TEC)
were established from tissue obtained during a glossect-
omy for a benign lesion and maintained in Keratinocyte-
SFM (Gibco, Invitrogen Corp, USA).
All cells were grown in 5% CO2 in a humidified at-
mosphere at 37°C.
Real-time PCR (RT-PCR)
Total RNA was extracted from cultured cells and fresh
tissues using TRIzol reagent (Invitrogen) according to
the manufacturer’s instruction and treated with RQ1
RNase-free DNase (Promega). cDNA was synthesized
Table 1 Clinicopathologic characteristics and GOLPH3
expression of patients with clinically N0 oral tongue
cancer of the study cohort (n = 179)





< 53 89 (49.7)




























Low or none expression 57 (31.8)
High expression 122 (68.2)
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(Bio-Rad Laboratories) and the quantitation of GOLPH3
mRNA was performed by qPCR using a SsoFast Eva-
Green Supermix (Bio-Rad Laboratories and a Bio-Rad
CFX96 sequence detection system). Cycling condition
included initial denaturation at 95°C for 30s followed by
40 cycles of 95°C for 5 s and 60°C for 5 s. Primers for
GOLPH3 and β-actin were designed using PrimerExpress Software v. 2.0 (Applied Biosystems). GOLPH3
expression data was normalized to β-actin and all
experiments were performed in triplicate.
Western blotting
Cells were washed twice with ice-cold phosphate-buf-
fered saline (PBS) and lysed on ice in RIPA (radio immu-
noprecipitation assay) buffer (Cell Signaling Technology,
Danvers, MA) containing complete protease inhibitor
cocktail (Roche Applied Science, Mannheim, Germany).
Fresh tissue samples were ground to powder in liquid
nitrogen and lysed with SDS-PAGE sample buffer. Pro-
tein samples (20 μg) were separated on 12% SDS-
polyacrylamide gels and transferred to PVDF mem-
branes (Immobilon P, Millipore, Bedford, MA).
Membranes were blocked with 5% fat-free milk in
Tris-buffered saline containing 0.1% Tween-20 (TBST)
for 1 h at room temperature. Membranes were incu-
bated with anti-GOLPH3 antibody (1:1000, Abcam,
ab69179) overnight at 4°C, then with horseradish
peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz
Biotechnology, SC-2004), and GOLPH3 expression was
detected using ECL prime Western blotting detection
reagent (Amersham) according to the manufacturer’s
instructions. β-actin was used as a loading control.
Immunohistochemistry
Immunohistochemical analysis was used to measure
GOLPH3 protein expression in 179 human oral tongue
cancer tissues. Immunohistochemistry methods and
scoring for GOLPH3 expression were done as previously
described. Briefly, paraffin-embedded specimens were
cut into 4 μm sections and baked at 60°C for 2 h fol-
lowed by deparaffinization with xylene and rehydration.
Sections were then submerged in EDTA antigenic re-
trieval buffer and microwaved for antigenic retrieval,
treated with 3% hydrogen peroxide in methanol to
quench endogenous peroxidase activity, and incubated
with 1% bovine serum albumin to block nonspecific
binding. Sections were then incubated with anti-
GOLPH3 rabbit polyclonal antibody (1:100, Abcam,
ab69179) at 37°C for 40 min. Normal goat serum was
used as a negative control. After washing, tissue sections
were incubated with biotinylated anti-rabbit secondary
antibody (Zymed), then with streptavidin-horseradish
peroxidase complex (Zymed). Finally, sections were
immersed in 3.30-diaminobenzidine, counterstained with
10% Mayer’s hematoxylin, dehydrated, and mounted.
GOLPH3 staining was scored independently by two
pathologists. The proportion of positive tumor cell was
scored as: 0, no positive tumor cells; 1, 1%–10% positive
tumor cells; 2, 11%–35% positive tumor cells; 3, 36%–
70% positive tumor cells; and 4, >70% positive tumor
cells. Staining intensity was scored as: 0, no staining; 1,
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brown); and 3, strong staining (brown). The staining
index for GOLPH3 expression in oral oral tongue cancer
lesions was calculated by multiplying the two scores
obtained for each sample and obtained values of 0, 1, 2,
3, 4, 6, 9, or 12. A score of >6 was defined as high
GOLPH3 expression and scores of <4 defined low
GOLPH3 expression.Figure 1 Overexpression of GOLPH3 mRNA and protein in
tongue cancer cell lines. (A and B) Expression of GOLPH3 mRNA
and protein in tongue cancer cell lines (SCC-9, SCC-25, CAL-27,
TSCCa, Tca-8113) and TEC were examined by qPCR (A) and WesternStatistical analyses
All statistical analyses were carried out using the SPSS
software package (IBM, standard version 17.0). Pearson’s
χ2 and Fisher’s exact tests were used to analyze the rela-
tionship between GOLPH3 expression and clinicopatho-
logical characteristics. Overall survival was defined as
the time from surgery to death, and disease-free survival
was defined as the time from surgery to the onset of re-
currence (diagnosed by clinical assessment or imaging).
Kaplan–Meier survival curves were plotted and com-
pared using a log-rank test. Multivariate survival analysis
was performed for all parameters found to be significant
in the univariate analysis using the Cox regression
model. A two-sided probability value of less than 0.05
was considered to be statistically significant.blotting (B). Expression levels were normalized to β-actin. Error bars
represent standard deviation of the mean (SD) calculated from three
parallel experiments.Results
GOLPH3 is overexpressed in oral tongue cancer cell lines
In order to investigate the potential role of GOLPH3 in
the tumorigenesis of oral tongue cancer, the expression
of GOLPH3 mRNA and protein were determined for
four oral tongue cancer cell lines (SCC-25, CAL-27,
TSCCa and Tca-8113) and compared with GOLPH3 ex-
pression in primary cultured normal tongue epithelial
cells (TEC). GOLPH3 mRNA expression was at least 5-
fold higher in oral tongue cancer cell lines than that in
TEC (Figure 1A), and GOLPH3 protein was highly
expressed in oral tongue cancer cell lines and only
weakly expressed in TEC (Figure 1B).GOLPH3 is overexpressed in oral tongue cancer tissues
To investigate GOLPH3 mRNA and protein expression
in cN0 oral tongue cancer, RT-PCR and Western blot-
ting analyses were done on eight matched pairs of oral
tongue cancer samples (T) and adjacent noncancerous
tissue samples (N). GOLPH3 mRNA was expressed at
higher levels in all oral tongue cancer tissue samples
than that in adjacent noncancerous tissues, with differ-
ential expression ranging from 2.2-fold to 24.1-fold
(Figure 2A). Consistent with this data, GOLPH3 protein
was also up-regulated in cN0 oral tongue cancers com-
pared with the matched controls (Figure 2B).GOLPH3 overexpression is associated with clinical
features of cN0 oral tongue cancer
We further investigated the link between GOLPH3 pro-
tein expression and the clinicopathological characteris-
tics of oral tongue cancer using a panel of 179
paraffin-embedded, archived oral tongue cancer speci-
mens, including 80 stage I tumors, 67 stage II tumors,
17 stage III tumors, and 15 stage IV tumors. GOLPH3
expression was analyzed by immunohistochemical stain-
ing with an anti-GOLPH3 antibody. As shown in Table 1,
167 of the total 179 oral tongue cancers (93.2%) were
positive for GOLPH3 based on immunohistochemical
staining. High GOLPH3 protein expression was detected
in 122 samples (68.2%) and weak or negative staining
was observed in 57 tumor samples (31.8%, Figure 3).
Statistical analysis showed a strong correlation be-
tween GOLPH3 expression, as determined using immu-
nohistochemical staining, and clinicopathological
characteristics of cN0 oral tongue cancer, including clin-
ical stage (P =0.001), T classification (P= 0.001), N classi-
fication (P =0.043), and recurrence (P =0.021). In
contrast, GOLPH3 expression did not correlate with age,
gender and tumor differentiation (Table 2). Furthermore,
Spearman correlation analysis determined that the level
of GOLPH3 overexpression correlated with clinical stage
Figure 2 The overexpression of GOLPH3 protein was in tongue
cancers. (A) Average T/N ratios of GOLPH3 mRNA expression in
paired tongue cancer (T) and adjacent noncancerous tissues (N) was
quantified by qPCR and normalized to β-actin. Error bars represent
standard deviation of the mean (SD) calculated from three parallel
experiments. (B) Representative Western blotting analyses images of
GOLPH3 protein expression in four matched pairs of oral tongue
cancer (T) and adjacent noncancerous tissues (N). β-actin was the
loading control.
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(P= 0.021), recurrence (P= 0.001) and vital status
(P= 0.01). Taken as a whole, our data shows that
GOLPH3 protein overexpression positively correlatesFigure 3 The expression of GOLPH3 protein in oral tongue cancer sec
tongue cancer tissue specimens indicating strong GOLPH3 staining (A and
detectable GOLPH3 staining (E and F). Magnification is × 200 (A, C and E) owith pathological stage, T classification, N classification,
recurrence and vital status, and GOLPH3 overexpression
occurs during the clinical progression of oral tongue
cancer.
Association between GOLPH3 expression and
patient survival
Patient survival analysis showed a clear negative correl-
ation between the level of GOLPH3 protein expression
and both the overall survival and disease-free survival of
patients with cN0 oral tongue cancer (P= 0.010 and
0.009, respectively; Figure 4A, B). The cumulative 5-year
overall and disease-free survival rates for patients with
high levels of GOLPH3 expression were found to be
62.3% and 61.5%, respectively, whereas for patients with
low or no GOLPH3 expression the rates were 80.7% and
80.4%, respectively. Cox regression revealed that only N
classification (relative risk, 1.859, CI: 1.353–2.559,
P < 0.001) and GOLPH3 overexpression (relative risk,
2.064, CI: 1.061–4.015, P= 0.033) were independent
prognostic factors for poor overall survival.
Discussion
As the most common cancer diagnosed in the oral cav-
ity, tongue squamous cell carcinomas comprise 25%–
40% of all oral carcinomas [14]. The poor prognosis of
oral tongue cancer is mainly a consequence of its un-
usual histological makeup (including a rich lymphatic
network and a highly muscularized structure), which
makes it poorly equipped to resist invasion and metasta-
sis [15]. In clinical practice, the most important prognos-
tic factors are tumor size, nodal involvement, and depth
of infiltration, although this system cannot reliably pre-
dict the clinical outcome or provide useful information
concerning the biologic characteristics of the malignancytions. Representative immunohistochemical images of cN0 oral
B); moderate GOLPH3 staining (C and D); and weak or negative
r × 400 (B, D and F).
Table 2 Correlation between GOLPH3 expression and clinicopathologic characteristics of patients with clinically N0
oral tongue cancer
Characteristics n GOLPH3 expression χ2 test P
Low or none, no. (%) High, no. (%) (Fisher’s exact test P)
Gender 0.574
Male 109 33 (30.3) 76 (69.7)
Female 70 24 (34.3) 46 (65.7)
Age (years) 0.594
< 53 89 30 (33.7) 59 (66.3)
≥ 53 90 27 (30.0) 63 (70.0)
clinical stage 0.001
I 80 39 (48.8) 41 (51.2)
II 67 14 (20.9) 53 (79.1)
III 17 1 (5.9) 16 (94.1)
IV 15 3 (20) 12 (80)
T classification 0.001
T1 87 39 (44.8) 48 (55.2)
T2 87 16 (18.4) 71 (81.6)
T3 5 2 (40.0) 3 (60.0)
N classification 0.043
N0 149 53 (35.6) 96 (64.4)
N1 15 1 (6.7) 14 (93.3)
N2 15 3 (20.0) 12 (80.0)
Pathologic differentiation 0.338
Well 136 46 (33.3) 90 (66.7)
Moderately 36 8 (22.2) 28 (77.8)
Poorly 7 3 (42.9) 4 (57.1)
Recurrence 0.009
No 120 45 (37.5) 75 (62.5)
Yes 59 11 (18.6) 48 (81.4)
Vital status (at follow-up) 0.010
Alive 122 46 (37.8) 76 (62.2)
Dead 57 11 (19.3) 46 (80.7)
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nosis of oral tongue cancer, no reliable prognostic bio-
markers for oral tongue cancer are available for clinical
use. Improving prognostic markers are urgently needed,
as survival rates for patients with tumors at the same
clinicopathological stage vary considerably.
In the current study, we have demonstrated the clin-
ical significance of GOLPH3 overexpression in cN0 oral
tongue cancer for the first time. We also investigated the
potential for GOLPH3 expression level to be a clinical
prognostic indicator for disease progression and patient
survival in cN0 oral tongue cancer. We found that
GOLPH3 was highly expressed in cN0 oral tongue
cancer cell lines and tissue samples at both thetranscriptional and translational levels, and that
GOLPH3 protein overexpression correlated with the
clinical features of cN0 oral cancer, including clinical
stage, T classification, N classification, nodal status, vital
status and prognosis. Furthermore, the cumulative 5-
year overall and disease-free survival rates of patients
with high GOLPH3 expression are lower than those with
low or undetectable GOLPH3 expression. Thus, patients
with high GOLPH3 expression have a poorer prognosis
than those with low or absent GOLPH3 expression,
making GOLPH3 a potential independent prognostic
factor for cN0 oral tongue cancer.
GOLPH3 was originally identified following proteomic
characterization of the Golgi apparatus, and GOLPH3
Figure 4 The level of GOLPH3 protein expression affects overall survival and disease-free survival. Kaplan–Meier curves with univariate
analysis (log-rank) for cN0 oral tongue cancer patients with high GOLPH3 expression (n = 57) versus low or no GOLPH3 expression (n = 122) for
overall survival (A) and disease-free survival (B).
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and MYO18A to provide a tensile force required for effi-
cient tubule and vesicle formation [9-11]. GOLPH3 plays
an important role in malignant transformation and cell
growth by regulating the localization of protein glycosyl-
transferases to the Golgi [16,17]. Recent studies identi-
fied a role for GOLPH3 in regulating various biological
processes during tumorigenesis and GOLPH3 has been
associated with the progression and outcome of many
tumor types. An increasing number of studies have
found GOLPH3 upregulation in several types of cancers,
thus indicating a role for GOLPH3 as a positive regula-
tor of cancer progression.
Furthermore, GOLPH3 overexpression correlates with
hyperactivation of mTORC2 and mTORC1 signaling in
human cells [12]. Xenograft experiments revealed that
tumor cells overexpressing GOLPH3 have an increased
sensitivity to the mTORC1 inhibitor, rapamycin, and
GOLPH3-dependent oncogenesis is associated with
increased mTOR signaling [13]. The serine/ threonine
protein kinase, mTOR, is a primary regulator of protein
synthesis and cell growth that integrates diverse up-
stream signals including amino acid and energy stress
sensing to regulate cell proliferation, growth and sur-
vival. The regulation of cell size by mTOR[18-20] may
be important for cancer development, progression, and
metastasis. Cell growth, proliferation, and survival are
regulated by a complex network of intracellular and
extracellular signal transduction cascades. The growth
factor-responsive receptor tyrosine kinase (RTK) phos-
phatidylinositol 3-kinase (PI3K) pathway plays a key role
in governing these processes [15]. In addition, the
serine/threonine kinase AKT functions as a central inte-
grator of RTK–PI3K signaling to modulate downstream
effectors, notably the TSC1/2-mTOR complexes.
GOLPH3 can enhance downstream growth signalingin response to RTK activation [13]. We therefore
hypothesize that GOLPH3 may affect the development
and progression of cN0 oral tongue cancer through the
PI3K–AKT–mTOR signaling pathway.
In this study, we investigated GOLPH3 mRNA and
protein expression levels in a series of cN0 oral tongue
cancer samples. We found that GOLPH3 was highly
expressed in cN0 oral tongue cancer cell lines and tis-
sues at both the transcriptional and translational levels,
consistent with the hypothesis that GOLPH3 is an onco-
gene. Elevated levels of GOLPH3 protein positively cor-
related with several clinicopathologic characteristics of
cN0 oral tongue cancer, including pathological stage, T
classification, N classification, and nodal status. More-
over, cN0 oral tongue cancer patients with increased
GOLPH3 expression had significantly shorter overall
and disease-free survival time than patients with lower
or no GOLPH3 expression (P= 0.010 and P= 0.009, re-
spectively). We therefore report that GOLPH3 is a risk
factor for cN0 oral tongue cancer, as the upregulation of
GOLPH3 in cN0 oral tongue cancer patients indicates a
poor prognosis. Thus, the detection of overexpressed
GOLPH3 in cN0 oral tongue cancer should identify
high-risk tumor phenotypes that require more aggressive
primary surgery or adjuvant treatment following surgery.
However, while our studies offer some insight into the
function of GOLPH3 in tongue squamous cell carcin-
oma, the underlying mechanism of GOLPH3-mediated
oral tongue cancer progression, the role of GOLPH3 in
malignant transformation and cell growth and its effects
on clinical outcome remain to be defined.
In conclusion, we have demonstrated an important
role for GOLPH3 in cN0 tongue carcinogenesis. We
suggest that determining GOLPH3 expression levels in
cN0 oral tongue cancers may help to identify patients
harboring occult micrometastases that require more
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current TNM classification to enable better risk stratifi-
cation and election for adjuvant therapy. We further
propose that targeting GOLPH3 may be a useful strategy
for developing novel therapeutic modalities.
Conclusions
In this study, we found that up-regulation of GOLPH3
correlated with poor prognosis and reduced survival of
patients with cN0 oral tongue cancer. Multivariate ana-
lysis showed that GOLPH3 protein levels could be used
as an independent prognostic predictor for cN0 oral
tongue cancer patients. Thus, testing the GOLPH3 pro-
tein level may be useful for formulating prognosis and
guiding the follow-up schedule in patients with cN0 oral
tongue cancer.
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